



CASE 4-20890C

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV365588439US
Express Mail Label Number

1/27/2004
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

CUENOUD ET AL.

APPLICATION NO: 10/696,488

FILED: OCTOBER 29, 2003

FOR: 2'-SUBSTITUTED NUCLEOSIDES AND OLIGONUCLEOTIDE
DERIVATIVES

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:


This paper is being filed within three months of the filing date of the application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form PTO-1449.

The listed references are of record in parent Application No. 09/194,844 filed May 14, 1999, and copies are available therein. However, applicants are willing to send copies of any or all of these references at the Examiner's request.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,



George R. Dohmann
Attorney for Applicants
Reg. No. 33,593
(862) 778-7824


Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080

Date: 1/27/2004

INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO.
4-20890/A/PCT
APPLICATION NO.
09/194,844
APPLICANT
CUENOUD ET AL.
FILING DATE May 14, 1999

Group



(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	5,750,673	5/12/98	Martin	536	26.1	
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	AM	2,123,241	11/13/94	CA (E P 0626387)			<input type="checkbox"/>	<input type="checkbox"/>
	AN	0 679 657	11/2/95	EP (see US 5,750,673)			<input type="checkbox"/>	<input checked="" type="checkbox"/>
	AO	41 10 085	10/1/92	DE (see English Abstract)			<input type="checkbox"/>	<input checked="" type="checkbox"/>
	AP	WO 91/06556	5/16/91	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AQ	WO 91/15499	10/17/91	PCT			<input type="checkbox"/>	<input type="checkbox"/>


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Beaucage et al., Tetrahedron Report Number 309, Vol. 48, No. 12, pp. 2223-2311 (1991)
AS	Cohen J. et al., Scientific American, The New Genetic Medicines, pp. 50-55 (1994)
AT	Crooke et al, International ISBN 3-540-58890-6, Medical Intelligence Unit, Therapeutic Applications of Oligonucleotides, R. G. Landes Company, Austin

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.



INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AU	De Mesmaecker et al., Current Opinion in Structural Biology, Vol. 5, pp. 343-355 (1995)
AV	Douglas M. et al., Pergamon, Bioorg. & Medicinal Chemistry Letters, Vol. 4, No. 8, pp. 995-1000 (1994)
AW	Inoue et al., Nucleic Acids Research, Vol. 15, No. 15, pp. 6131-6148 (1987)
AX	Iribarren A., et al., Biochemistry, Proc. Natl. Acad. Sci., USA, Vol. 87, pp. 7747-7751 (1990)
AY	Keller et al., Helvetica Chimica Acta., Vol. 76, pp. 884-892 (1993)
AZ	Keller et al., Nucleic Acids Research, Vol. 21, No. 19, pp. 4499-4505 (1993)
BA	Lesnik. et al., Biochemistry, Vol. 32, pp. 7832-7838 (1993)
BB	Manoharan M. et al., Tetrahedron Letters, Vol. 32, No. 49. pp. 7171-7174 (1991)
BC	Martin P., Helvetica Chimica Acta, Vol. 78, pp. 486-504 (1995)
BD	Plum G. et al., Annu. Rev. Biophys. Biomol. Struct., Vol. 24, pp. 319-350 (1995)
BE	Stull R. et al., Phamaceutical Research, Vol. 12, No. 4, pp. 465-483 (1995)
BF	Abstract 92-332937 (DE 4110 085, 11/15/93)
BG	Copy of International Search Report
AN	


EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



ATTY. D. ET NO.
4-20890/AT-CT
APPLICATION NO.
09/194,844
APPLICANT
CUENOUD ET AL.
FILING DATE May 14, 1999

Sheet 3 of 3

Group

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AA	92/03568	3/5/92	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AB	93/07883	4/29/93	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AC	93/13121	7/8/93	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AD	93/17717	9/16/93	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AE	94/02501	2/3/94	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AF	95/03568	3/5/92	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AG	95/06659	3/9/95	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AH						<input type="checkbox"/>	<input type="checkbox"/>
	AI						<input type="checkbox"/>	<input type="checkbox"/>
	AJ						<input type="checkbox"/>	<input type="checkbox"/>
	AK						<input type="checkbox"/>	<input type="checkbox"/>
	AL						<input type="checkbox"/>	<input type="checkbox"/>
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>
	AR						<input type="checkbox"/>	<input type="checkbox"/>
	AS						<input type="checkbox"/>	<input type="checkbox"/>
	AT						<input type="checkbox"/>	<input type="checkbox"/>
	AU						<input type="checkbox"/>	<input type="checkbox"/>
	AV						<input type="checkbox"/>	<input type="checkbox"/>
	AW						<input type="checkbox"/>	<input type="checkbox"/>
	AX						<input type="checkbox"/>	<input type="checkbox"/>
	AY						<input type="checkbox"/>	<input type="checkbox"/>
	AZ						<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.